Chronic Disease
Recent clinical, regulatory, research and industry developments relating to this disease.
Neural Plasticity in Migraine Chronification.
Systematic low-grade chronic inflammation and intrinsic mechanisms in polycystic ovary syndrome.
Microplastics and human health: unveiling the gut microbiome disruption and chronic disease risks.
2024 ESC Guidelines for the management of chronic coronary syndromes.
Inflammation unites diverse acute and chronic diseases.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- Active recent publication activity.
- 2 clinical trials with recent milestones.
- 5 industry developments reported.
Research HighlightsViewHide
Clinical MilestonesViewHide
Industry & MarketViewHide
- 2026-11-01[Editorial] Neurotrauma as a chronic disease: a call for integrated careIndustry · The Lancet Neurology
- 2026-09-28More data tie ultra-processed foods to chronic disease, deathIndustry · Healio Cardiology
- 2026-09-11Joint associations of air pollution and residential greenness with chronic disease in a longitudinal Chinese cohortIndustry · Nature — Environmental Sciences
- 2026-07-08Bryan Johnson’s chronic disease is notoriously difficult to diagnoseIndustry · STAT News
- 2026-06-23STAT+: Cadence raises $100 million to automate chronic disease care with regulated AIIndustry · STAT News
Regulatory UpdatesView all 7Hide
- 2026-10-30Product authorisation ended — IndacaterolHirobriz Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.
- 2026-10-30Product authorisation ended — IndacaterolOslif Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.
- 2026-09-18Generic approval — RuxolitinibMyelofibrosis (MF) Ruxolitinib Viatris is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. Polycythaemia vera (PV) Ruxolitinib Viatris is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea. Graft versus host disease (GvHD) Acute GvHD Ruxolitinib Viatris is indicated for the treatment of adults and paediatric patients aged 28 days and older with acute graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1). Chronic GvHD Ruxolitinib Viatris is indicated for the treatment of adults and paediatric patients aged 6 months and older with chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1).
- 2026-08-30Product authorisation ended — Glycopyrronium bromideEnurev Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
- 2026-05-29Original application approval — FurosemideBopediat is indicated in children from birth to less than 18 years of age for the treatment of oedema of cardiac or renal origin, oedema of hepatic origin, and hypertension in patients with chronic kidney disease.
- 2026-04-14Product authorisation ended — LusutrombopagMulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures
- 2026-11-01Industry[Editorial] Neurotrauma as a chronic disease: a call for integrated careIndustry · The Lancet Neurology
- 2026-10-30RegulatoryProduct authorisation ended — IndacaterolHirobriz Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.
- 2026-10-30RegulatoryProduct authorisation ended — IndacaterolOslif Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.
- 2026-09-30ClinicalStudy and Design of New Sustainable Exercise and Dietary-nutritional Programs for the Treatment of Metabolic Disorders in Elderly WomenPrimary completion
- 2026-09-28IndustryMore data tie ultra-processed foods to chronic disease, deathIndustry · Healio Cardiology
- 2026-09-18RegulatoryGeneric approval — RuxolitinibMyelofibrosis (MF) Ruxolitinib Viatris is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. Polycythaemia vera (PV) Ruxolitinib Viatris is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea. Graft versus host disease (GvHD) Acute GvHD Ruxolitinib Viatris is indicated for the treatment of adults and paediatric patients aged 28 days and older with acute graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1). Chronic GvHD Ruxolitinib Viatris is indicated for the treatment of adults and paediatric patients aged 6 months and older with chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1).
- 2026-09-11IndustryJoint associations of air pollution and residential greenness with chronic disease in a longitudinal Chinese cohortIndustry · Nature — Environmental Sciences
- 2026-08-30RegulatoryProduct authorisation ended — Glycopyrronium bromideEnurev Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
- 2026-07-08IndustryBryan Johnson’s chronic disease is notoriously difficult to diagnoseIndustry · STAT News
- 2026-06-23IndustrySTAT+: Cadence raises $100 million to automate chronic disease care with regulated AIIndustry · STAT News
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Original application approval — Asthma Exdensur is indicated as add-on maintenance treatment for severe asthma with… (2026)
Original application approval — Bopediat is indicated in children from birth to less than 18 years of age for the treatme… (2026)
Product authorisation ended — Enurev Breezhaler is indicated as a maintenance bronchodilator treatment to relieve sympt… (2026)
Product authorisation ended — Hirobriz Breezhaler is indicated for maintenance bronchodilator treatment of airflow obst… (2026)
Product authorisation ended — Mulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with… (2026)
Generic approval — Myelofibrosis (MF) Ruxolitinib Viatris is indicated for the treatment of disease-… (2026)
Generic approval — Nintedanib Viatris is indicated in adults for the treatment of idiopathic pulmonary fibro… (2025)
Generic approval — Psoriatic arthritis Apremilast Accord, alone or in combination with Disease Modifying Ant… (2024)
Biosimilar approval — Allergic asthma Omlyclo is indicated in adults, adolescents and children (6 to <12 yea… (2024)
Original application approval — Vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidn… (2023)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Inflammation3
- Antioxidants2
- Brain Injuries, Traumatic2
- Cardiology2
- Communicable Diseases2
- Cost of Illness2
- Epidemiologic Research Design2
- Heart Failure2
Leading journals6
- European heart journal7
- Frontiers in immunology7
- International journal of molecular sciences5
- The Journal of neuroscience : the official journal of the Society for Neuroscience4
- European journal of epidemiology3
- The New England journal of medicine3
Leading researchers8
- Jaarsma T3
- Stricker BH3
- Uitterlinden AG3
- Adamo M2
- Alomar SY2
- Alwasel SH2
- Bjermer L2
- Čelutkienė J2
Affiliations (unnormalised)6
- Aarhus University Hospital3
- Brigham and Women's Hospital3
- Ghent University Hospital3
- Medical University of Vienna3
- Amsterdam University Medical Centres2
- Charles University and Thomayer Hospital2
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Chronic disease refers to a class of illnesses that are long-lasting, may be permanent, and can leave residual disability or require prolonged supervision, observation, or care. In epidemiological use, it often includes conditions such as heart disease, stroke, cancer, and type 2 diabetes mellitus.
The grounding does not support a single cause or aetiology for chronic disease as a category. It is described as encompassing diseases with persistent or nonreversible pathological alteration rather than having one unified cause.
The literature grounding treats chronic disease as a broad category associated with shared biological processes rather than one mechanism. Reported mechanisms across chronic diseases include oxidative stress, chronic inflammation and cytokine signaling, altered signal transduction, aging-related changes, wound healing and tissue remodeling, neuronal plasticity, and matrix metalloproteinase-mediated extracellular matrix turnover.
Supported risk factors in the grounding are broad and mechanism-linked rather than disease-specific. These include psychological stress, diet, lifestyle factors, aging, cigarette smoking, pollution, radiation, certain drugs, and prior child maltreatment as a long-term risk factor for later mental and physical health outcomes.
The grounding does not support a single standard treatment for chronic disease as a category. It indicates that management is disease-specific and may involve targeted therapies in some chronic inflammatory diseases, along with rehabilitation, long-term supervision, and care.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.